Q2 FY27 earnings call · November 16, 2026
Jubilant Pharmova Q2 FY27 Earnings Call: Revenue Up 21%, Guides Mid-Teens H2 Margins (JUBLPHARMA)
Listen to the earnings call
Quick summary
Jubilant Pharmova Ltd held its Q2 FY27 earnings call on November 13, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.
Strong Top Line, Compressed Margins
- Q2 FY 2026-2027 revenue up 21% YoY to Rs.2,370 crore — growth across CDMO sterile injectables, allergy, radiopharma and generics; EBITDA of Rs.255 crore and PAT of Rs.31 crore.
- H1 FY 2026-2027 revenue grew 19% to Rs.4,599 crore — with EBITDA of Rs.523 crore and PAT of Rs.87 crore.
- EBITDA margins declined YoY in both Q2 and H1 FY 2026-2027 — management attributed this to unavailability of high-margin spec radiopharma products, negligible third-party revenues, higher operating expenses, and incremental remediation costs at the CDMO Montreal facility.
- Rs.800 crore of non-convertible debentures raised — successfully completed during the quarter.
- H2 FY 2026-2027 outlook — management expects revenue growth momentum to continue and margins to improve quarter on quarter, with H2 FY 2026-2027 average margins in the mid-teens.
The Margin Drag and the Path Back
- Montreal facility lost more than Rs.80 crore in Q2 FY 2026-2027 — covering remediation costs and OpEx, with no third-party revenue coming in; H1 FY 2026-2027 losses were about Rs.157 crore, after about Rs.200 crore before that, on a cumulative basis.
- Remediation costs should decrease — Harshav Singh said costs should fall by "substantially... more than low double digits, Q over Q" (period unspecified), with quarter-over-quarter improvements in spend at Montreal expected.
- Radiopharma margins fell from 40% to 32% over the last four quarters — per Nuvama analyst Shrikant Akolkar; CFO Mukirwar guided spec supply to normalize, particularly in Q4 FY 2026-2027, moving the radiopharma margin back toward 40%.
- RUBY-FILL margins are currently below the overall radiopharma margin — so as RUBY-FILL's contribution rises due to unavailable Montreal spec products, the overall radiopharma margin falls; management declined to give product-level margins.
- SPECT margin structure expected roughly stable in FY 2027-2028 — with declining tech-transfer OpEx as Montreal is de-risked; two significant radiopharma launches are planned for the back half of 2028, expected to be margin-accretive but with associated SG&A.
- Montreal H2 FY 2026-2027 burn should be lower than H1 — with spec production expected to help absorb costs and remediation costs declining as production normalizes into FY 2027-2028; the company is past the 90-day threshold after the Montreal warning letter.
Line 3 Ramp, Line 4 Pipeline Building
- Line 3 generated about $20 million of revenue in Q2 FY 2026-2027 — from 13+ tech transfer projects and 5+ customers; double-digit revenue growth expected in H2 FY 2026-2027 and FY 2027-2028, driven by demand for US isolator capacity amid geopolitical uncertainty and market consolidation.
- Line 3 peak revenue attainment is expected 1.5 to 2 years later than original McKinsey modeling projections — management still holds to its full-year utilization projection of $80-90 million, with line 3 close to full utilization in FY 2027-2028.
- Line 4 build-out is complete and media fills were completed in Q2 FY 2026-2027 — a major qualification step; tech transfers for "a project or two" are on track to start by Q4 FY 2026-2027, with more customers expected to sign and tech transfer work continuing into FY 2027-2028.
- 23 active proposals for line 4 capacity buys — Chris Preti cited a book of business and RFPs at its "strongest point ever," plus 51 live customer meetings at the CPHI international manufacturing meeting about three weeks before the call.
- Line 4 peak revenue attainment of 80 to 90 million projected within 1.5 to 2 years — the same timeline as line 3, applying line 3 learnings (five-plus customers and 13 projects) to line 4 qualification and product approval.
- CDMO margins under pressure until line 3 costs are fully absorbed — CFO Mukirwar said tech transfer carries higher labor costs and lower margins, with gradual improvement in FY 2027-2028 and significant margin improvement expected in FY 2028-2029; line 4 margin dilution guidance deferred to H2 FY 2026-2027.
- Spokane facility received VAI status and line 3 secured first product approval without a pre-approval inspection — cited by Preti as signs of the high quality bar customers demand; a master services agreement was signed with a large pharma customer for one of its largest global oncology products.
RUBY-FILL Expansion, PET Rollout, MIBG Filing
- RUBY-FILL growth tracking about 35% YoY — with Q2 FY 2026-2027 at 30% annualized; the FY 2026-2027 absolute growth run rate is higher than FY 2025-2026, and margins improved in Q2 FY 2026-2027.
- $67 million of capex announced to double manufacturing capacity — supporting RUBY-FILL growth, with capex of CAD 94.5 million; the Government of Canada agreed to provide support of CAD 23.8 million for the Ruby-Fill capex.
- New RUBY-FILL capacity expected online in the back half of FY 2029 — management expects efficient utilization to generate a return on capital of more than 20% on the investment (period unspecified).
- Cyclotrons deployed at 5 of 6 new PET sites — with 1 more coming shortly; 3 sites in final qualification, 2 mid-qualification, and 1 cyclotron being delivered; the first new PET site is expected online in Q3 FY 2028, with 2-3 sites starting that quarter and the remaining 3 over the next 2 quarters.
- Distribution contract signed with one of the largest PET providers in the category — which has submitted volume deliverables, with tech transfer packages starting now; the new sites are FDA GMP sites, and because products are radioactive, filing can follow quickly after tech transfer batches.
- MIBG NDA on track to file in "Q4 of 2027" — or very early the following quarter; the Optimum pivotal registration trial is completed and closed, with blinded independent review progressing well.
- PET CMO economics are stronger than pharmacy — Harshav Singh said cyclotrons are "substantially more profitable" than specialty pharmacy sites and "significantly EBITDA positive" individually and at network level; management declined to give segment-level revenue or EBITDA margin guidance for a mature PET site.
Launch Momentum vs API Pricing Pressure
- 13 ANDA approvals secured since April 2024 — when the previous USFDA inspection closed with VAI; the company is monetizing these launches, plus in-licensing fully packaged products and doing site transfers away from Rudki to avoid concentrating products in one site.
- 6 to 8 product launches per year guided for FY 2026-2027 — targeting products with lower competition, not necessarily complex or differentiated ones; generics margins expected to improve on new launches planned for Q3 FY 2026-2027 and Q4 FY 2026-2027.
- Generics EBITDA margin range of 15-17% reaffirmed — from the vision laid out in February 2025; Jaydev Rajpal said trailing twelve months and FY 2025-2026 are moving in that direction, and did not endorse the analyst's suggested 25-30% margin at roughly Rs.1,000 crore scale.
- API business at 2% in Q2 FY 2026-2027 — per Nuvama's Shrikant Akolkar, who noted API has declined since Q3 FY 2025-2026 and described the quarter as stable; CFO Mukirwar said API pricing pressure continues given the geopolitical scenario, with API expected to stay stable at the current run rate if conditions persist.
- FY 2027-2028 should be better for API if sovereign prices improve — per CFO Mukirwar, who will provide API guidance when the company enters the new year.
- Discovery ramp-up expected to continue significantly in FY 2027-2028 — with green shoots from Q4 FY 2026-2027; win rate is "much better than the industry," and Vision 2030 discovery targets continue to stand, though Mukirwar declined to confirm double-digit CC growth for FY 2027-2028.
- API custom manufacturing additive at Nanjangud — already serving one customer for an off-patent API and in discussions with one more big pharma; commercialization could happen sooner than the analyst's FY 2028-2029 estimate depending on the product.
Peak Capex Year, Deleveraging Toward FY30
- FY 2026-2027 capex guided at around Rs.1,800-1,900 crore — the company's highest capex cycle, covering RUBY-FILL new capacity, Line 4 and PET installation; capex expected to fall substantially to around Rs.1,000 crore in FY 2027-2028.
- Net debt guided closer to Rs.4,000 crores by end of FY 2026-2027 — per CFO Mukirwar; for FY 2027-2028, capex will be significantly lower and, if things go as planned, net debt is not expected to rise above the end-FY 2026-2027 level.
- Net debt zero by end of FY30 vision maintained — responding to Shashank Rastogi citing debt-to-EBITDA of 2.2x in Q2 FY 2026-2027, Mukirwar said the company is "maintaining its vision of net debt zero by end of FY30," with FY29 and FY30 expected to be significantly cash-generating years.
- EBITDA margins and cash flows should improve starting FY 2027-2028 — driven by new radiopharma launches, new PET pharmacies starting FY 2027-2028, and lines three and four reaching commercialized revenue starting FY28.
- JBI-802 in Phase 1/2 with 12 to 17 patients enrolled — management believes it is best in class based on initial data while noting Besremi (USFDA-approved in the same indication about three months earlier) carries a black box warning, but called this belief speculative; the company wants to complete the trial on its own before evaluating monetization, fundraising or out-licensing, with all options open.
- FY 2027-2028 guidance deferred — Harshav Singh said guidance will come on the next call and it is too early to guide now; management expects significant progress on new radiopharma products planned for launch in FY28 and FY29.
Ask about this
Ask Cofacto a question about this call. Answers cite filings and company data.
Companies on this page
Related
Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.